Oxazoles as mGluR1 enhancers
    2.
    发明授权
    Oxazoles as mGluR1 enhancers 有权
    恶唑类作为mGluR1增强子

    公开(公告)号:US07119113B2

    公开(公告)日:2006-10-10

    申请号:US10740245

    申请日:2003-12-18

    IPC分类号: A61K31/421 C07D263/30

    CPC分类号: C07D413/12

    摘要: The invention relates to carboxamide derivatives as defined in the specification and claims, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as mGluR1 enhancers in the treatment and prevention of neurological disorders and diseases, such as Alzheimer's disease and dementia.

    摘要翻译: 本发明涉及如说明书和权利要求书中定义的羧酰胺衍生物,其制备方法,包含它们的药物组合物及其作为mGluR1增强剂用于治疗和预防神经障碍和疾病如阿尔茨海默病和痴呆的用途 。

    Liposome compositions
    3.
    发明授权
    Liposome compositions 失效
    脂质体组成

    公开(公告)号:US07208174B2

    公开(公告)日:2007-04-24

    申请号:US11011266

    申请日:2004-12-14

    IPC分类号: A61K8/14 C07K16/00

    摘要: The present invention provides a non-covalent coupling method for the preparation of sterically stabilized lipsomes which may be used for targeted drug delivery, e.g., pegylated liposomes. The method simplifies the attachment of targeting vectors to sterically stabilized liposomes. The present invention also provides a liposome composition comprising a compound of the formula and a compound of the formula Z-Y, wherein Z is any compound capable of binding to a cellular receptor, and X and Y are compounds which can interact with each other non-convalently, and wherein the substituents n, F1 and F2 are as provided in the specification.

    摘要翻译: 本发明提供了用于制备空间稳定的lipomes的非共价偶联方法,其可用于靶向药物递送,例如聚乙二醇化脂质体。 该方法简化了靶向载体与空间稳定的脂质体的连接。 本发明还提供一种脂质体组合物,其包含下式的化合物和式ZY的化合物,其中Z是能够结合细胞受体的任何化合物,X和Y是可以互不相互作用的化合物 ,并且其中取代基n,F1和F2如说明书中所提供。

    Liposome compositions
    4.
    发明申请
    Liposome compositions 失效
    脂质体组成

    公开(公告)号:US20050152963A1

    公开(公告)日:2005-07-14

    申请号:US11011266

    申请日:2004-12-14

    摘要: The present invention provides a non-covalent coupling method for the preparation of sterically stabilized lipsomes which may be used for targeted drug delivery, e.g., pegylated liposomes. The method simplifies the attachment of targeting vectors to sterically stabilized liposomes. The present invention also provides a liposome composition comprising a compound of the formula and a compound of the formula Z-Y, wherein Z is any compound capable of binding to a cellular receptor, and X and Y are compounds which can interact with each other non-convalently, and wherein the substituents n, F1 and F2 are as provided in the specification.

    摘要翻译: 本发明提供了用于制备空间稳定的lipomes的非共价偶联方法,其可用于靶向药物递送,例如聚乙二醇化脂质体。 该方法简化了靶向载体与空间稳定的脂质体的连接。 本发明还提供一种脂质体组合物,其包含下式的化合物和式ZY的化合物,其中Z是能够结合细胞受体的任何化合物,X和Y是可以互不相互作用的化合物 ,并且其中取代基n,F1和F2如说明书中所提供。

    D-proline prodrugs
    7.
    发明授权
    D-proline prodrugs 有权
    D-脯氨酸前药

    公开(公告)号:US06903129B2

    公开(公告)日:2005-06-07

    申请号:US10307699

    申请日:2002-12-02

    CPC分类号: C07D207/16

    摘要: The invention relates to compounds of formulas wherein R1 and R2 are independently from each other lower alkoxy, lower alkenyloxy, benzyloxy, hydroxy, —OCH(CH3)OC(O)-lower alkyl or —OCH2C(O)N(R3)(R4), with the proviso that only one of R1 or R2 may be hydroxy; R3 and R4 are independently from each other and signify hydrogen, lower alkyl, lower alkenyl or cycloalkyl; or R1 and R2 form together with the carbon atom, to which they are attached the linking group X, wherein X is —O(CH2)nCH═CH(CH2)nO— or —O(CH2)mO—; n is 1, 2 or 3; and m is 4-8, or a pharmaceutically acceptable salt of said compound. Compounds of the present invention can be used for the treatment of diseases where Serum Amyloid P Component depletion has a beneficial effect, in particular in the treatment or prevention of central and systemic amyloidosis.

    摘要翻译: 本发明涉及下式的化合物,其中R 1和R 2彼此独立地为低级烷氧基,低级链烯氧基,苄氧基,羟基,-OCH(CH 3) (O) - 低级烷基或-OCH 2 C(O)N(R 3)(R 4) ,条件是R 1或R 2中只有一个可以是羟基; R 3和R 4彼此独立地表示氢,低级烷基,低级烯基或环烷基; 或R 1和R 2 +与连接基团X连接的碳原子一起形成,其中X是-O(CH 2)2, (CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 CH O-甲基; n为1,2或3; 和m为4-8,或所述化合物的药学上可接受的盐。 本发明的化合物可用于治疗其中血清淀粉样蛋白P组分消耗具有有益效果,特别是治疗或预防中枢和全身性淀粉样变性的疾病。